HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

PETS

PetMed Express, Inc. (NASDAQ)

Healthcare — Pharmaceutical Retailers

PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.

None 1 analysts
$1.96
$-0.03 (-1.51%)
Target: $2.15 (9.7%)
Sign in to add PETS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$42.53M
P/E Ratio (TTM)-
Forward P/E-66.33
EPS (TTM)$-2.74
Dividend Yield-
Profit Margin-32.00%
Revenue Growth-15.60%
ROE-100.44%
Debt/Equity1.85
Recommendation None
Analyst Target$2.15
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)72.1
Beta0.77
SMA 20-
SMA 40-
52-Week High$4.10
52-Week Low$1.57
50-Day Avg$2.07
200-Day Avg$2.52
Avg Volume673.1K
Volume29.3K

Performance Analysis

BEARISH

PETS is flashing more cautionary signals — investors should monitor closely.

~ Trading at 15% of its 52-week range.
- RSI at 72.1 indicates overbought conditions — a pullback may be due.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
- Revenue declined 15.6% year-over-year.
- Operating at a loss with -32.0% margin.
~ Wall Street consensus is "none" from 1 analysts.
+ Average analyst target of $2.15 implies 9.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:26 UTC

Back to Screener Export Report